Skip to main content
Premium Trial:

Request an Annual Quote

Italian Liquid Biopsy Tech Firm Tethis Secures €15M Investment

NEW YORK — Enea Tech and Biomedical Foundation said Tuesday that it has invested €15 million ($15.4 million) in Tethis, an Italian developer of liquid biopsy diagnostics for cancer.

Founded in 2004 as a spinout of the University of Milan, Tethis is advancing a novel method that uses nanomaterial-coated slides — dubbed SmartBioSurface slides — to isolate and capture cells in blood such as circulating tumor cells for analysis.

The company has also developed a sample preparation tool called See.d that stabilizes the cellular fraction on SmartBioSurface slides, which enables the analysis of immune and tumor cells while preserving plasma so that molecular analytes released from the tumor can be identified.

"This investment will accelerate the development, validation, and preparation for commercialization of our diagnostic platform," Tethis CEO Holger Neecke said in a statement. "Starting with a simple blood draw, we aim to provide oncologists and translational researchers with comprehensive cellular and molecular analyses that advance precision diagnostics, enable targeted therapeutic development, and ultimately deliver more personalized care for cancer patients."

Enea Tech and Biomedical Foundation is a private investment organization managed by the Italian Ministry of Enterprises and Made in Italy.